The Technical Analyst

Alnylam Pharmaceuticals [ALNY]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Alnylam Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

-0.47% $147.01

America/New_York / 16 apr 2024 @ 11:51

FIND ALL MARKETS FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo Live Signal Nasdaq Live Signal Crypto

Alnylam Pharmaceuticals: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap:	18 515 mill
EPS:	-3.52
P/E:	-41.76
Earnings Date:	May 02, 2024
SharesOutstanding:	125.95 mill
Avg Daily Volume:	0.854 mill

RATING 2024-04-15
B
Neutral

RATINGS
Rating CashFlow:	Strong Buy
Return On Equity:	Strong Buy
Return On Asset:	Neutral
DE:	Strong Sell
P/E:	Strong Sell
Price To Book:	Strong Sell

QUARTER GROWTHS
	3/22	4/22	1/23	2/23	3/23	4/23
Revenue
Gr.Profit
Ebit
Asset
Debt

PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -41.76 \| sector: PE -3.05

PE RATIO: COMPANY / INDUSTRY
-7.10x
Company: PE -41.76 \| industry: PE 5.88

DISCOUNTED CASH FLOW VALUE
N/A
N/A

Expected Trading Range (DAY)
$ 142.48 - 151.64 ( +/- 3.12%)
ATR Model: 14 days

Insider Trading

Date	Person	Action	Amount	type
2024-03-20	Fitzgerald Kevin Joseph	Sell	0	Common Stock
2024-03-20	Fitzgerald Kevin Joseph	Buy	0	Common Stock
2021-02-11	Fitzgerald Kevin Joseph	Sell	9 000	Performance Stock Option 2017 (right to buy)
2024-03-20	Fitzgerald Kevin Joseph	Sell	16 250	Stock Option (right to buy)
2024-03-20	Fitzgerald Kevin Joseph	Sell	6 667	Stock Option (right to buy)

INSIDER POWER
-6.09
Last 99 transactions
Buy: 237 064 \| Sell: 275 392

Forecast: 13:31 - $147.36

Live Trading Signals (every 1 min)

Forecast 1: 12:01 - $147.15

Forecast 2: 12:51 - $147.59

Forecast 3: 13:31 - $147.36

SCORE
-10.00
Sell

Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022

Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD

Volume Signals
Price	$147.01 (-0.47% )
Volume	0.0659 mill
Avg. Vol.	0.854 mill
% of Avg. Vol	7.71 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Alnylam Pharmaceuticals Inc

Last 12 Months

RSI

Intraday RSI14 chart for Alnylam Pharmaceuticals Inc

Last 10 Buy & Sell Signals For ALNY

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date	Signal	@	Closed	%
Feb 8 - 15:36	sell	$168.89	N/A	Active

ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Last 10 Buy Signals

Date	Signal	@
RIOUSD	Apr 16 - 11:50	1.590
GETHUSD	Apr 16 - 11:43	3 043.41
HEUSX	Apr 16 - 11:39	94.90
SXPUSD	Apr 16 - 11:48	$0.324
BTGUSD	Apr 16 - 11:47	$36.13
CHTR	Apr 16 - 11:47	$256.02
TWTUSD	Apr 16 - 11:43	$0.934
SCNSOLUSD	Apr 16 - 11:44	153.92
SAKAIUSD	Apr 16 - 11:43	2.88
MSOLUSD	Apr 16 - 11:43	152.06

Latest Press Releases

2024-04-11 07:20:00 - Press Release

Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - Alny

New york, ny / accesswire / april 11, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of alnylam pharmaceuticals, inc. ("alnylam") (nasdaq:alny) concerning possible violations of federal securities laws. on september 13, 2023, alnylam announced the u.s. food and drug administration's (fda) cardiovascular and renal drugs advisory committee (crdac) approved alnylam's application to expand approval for onpattro to attr-cardiomyopathy (cm) patients.

2024-04-10 07:25:00 - Press Release

Alny Stock Alert: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors Of An Ongoing Investigation

New york, ny / accesswire / april 10, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of alnylam pharmaceuticals, inc. ("alnylam") (nasdaq:alny) concerning possible violations of federal securities laws. on september 13, 2023, alnylam announced the u.s. food and drug administration's (fda) cardiovascular and renal drugs advisory committee (crdac) approved alnylam's application to expand approval for onpattro to attr-cardiomyopathy (cm) patients.

2024-04-09 07:30:00 - Press Release

Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - Alny

New york, ny / accesswire / april 9, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of alnylam pharmaceuticals, inc. ("alnylam") (nasdaq:alny) concerning possible violations of federal securities laws. on september 13, 2023, alnylam announced the u.s. food and drug administration's (fda) cardiovascular and renal drugs advisory committee (crdac) approved alnylam's application to expand approval for onpattro to attr-cardiomyopathy (cm) patients.

2024-04-08 07:20:00 - Press Release

Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates At Levi & Korsinsky Investigate - Alny

New york, ny / accesswire / april 8, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of alnylam pharmaceuticals, inc. ("alnylam") (nasdaq:alny) concerning possible violations of federal securities laws. on september 13, 2023, alnylam announced the u.s. food and drug administration's (fda) cardiovascular and renal drugs advisory committee (crdac) approved alnylam's application to expand approval for onpattro to attr-cardiomyopathy (cm) patients.

2024-04-07 08:00:00 - Press Release

Alnylam Presents Positive Results From The Kardia-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled Hypertension

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced positive results from the kardia-2 phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan). zilebesiran is an investigational rnai t.

Latest News

2024-04-08 09:46:05 - Zacks Investment Research

Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick

Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Full Story

2024-03-20 08:00:00 - Business Wire

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, at the American College of Cardiology (ACC) Scientific Session on Sunday, April 7, 2024 at 7:00 pm ET. The event will include pr.

Full Story

2024-03-06 12:30:18 - Zacks Investment Research

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.

Full Story

2024-02-16 13:11:04 - Zacks Investment Research

Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%

Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.

Full Story

2024-02-15 13:16:06 - Seeking Alpha

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript

Full Story

2024-02-15 12:39:02 - The Motley Fool

Why Alnylam Pharmaceuticals Stock Is Sinking Today

Alnylam reported mixed fourth-quarter results. The company also announced changes to its Helios-B phase 3 study of vutrisiran in ATTR-CM.

Full Story

2024-02-15 11:31:08 - Zacks Investment Research

Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Full Story

2024-02-08 11:05:47 - Zacks Investment Research

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Full Story

2024-01-12 10:35:06 - Seeking Alpha

Alnylam's Huge Opportunity

Pfizer's drug tafamidis has shown positive results in treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), but there is still room for improvement. Alnylam's gene silencer treatments, ONPATTRO and vutrisiran, have shown promise in reducing levels of the transthyretin protein in the body. Alnylam's Phase 3 trial for vutrisiran in ATTR-CM, HELIOS-B, is expected to release results in early 2024 and could be a game changer in the market.

Full Story

2024-01-08 15:02:08 - Zacks Investment Research

Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues

Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.

Full Story

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.